A new therapy to regenerate neurons for Alzheimer's disease
Official title: Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial
Funded at Neuronascent, INC. · NIH-10908602 · Data updated 2026-11-12
This study is testing a new treatment called NNI-362 that hopes to help people with Alzheimer's by encouraging the growth of new brain cells and reducing harmful proteins, and if successful, it could offer a way to improve their condition over six months.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neuronascent, INC. NIH-funded |
| Lab location | 1 site (Clarksville, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $2,093,556 |
| NIH project number | 5U01AG082687-02 |
| Project ID | NIH-10908602 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease.
✕Less likely to help
Patients with other forms of dementia or those who are not diagnosed with Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on a novel therapy called NNI-362, which aims to regenerate neurons in patients with Alzheimer's disease. The therapy has shown promise in early trials by promoting the growth of new neurons and reducing harmful brain proteins associated with the disease. The project involves scaling up the production of NNI-362 and testing its safety in animal models before moving to human trials. Patients may benefit from this innovative approach that seeks to reverse some effects of Alzheimer's over a six-month treatment period.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that helps regenerate brain cells and improve cognitive function in Alzheimer's patients.
How similar studies have gone: Previous research has shown promise in neuron regeneration therapies, but this specific approach with NNI-362 is novel and has not been extensively tested in humans yet.
Where this research is happening
-
Neuronascent, INC.
Clarksville, United States Active
Researchers
- Principal investigator: Kelleher-Andersson, Judith a — Neuronascent, INC.
- Study coordinator: Kelleher-Andersson, Judith a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.